Drugmaker Laurus Labs reported consolidated net profit for the March quarter surged to ₹233.87 crore from ₹75.32 crore a year earlier on a 19% increase in the revenue.
Revenue from operations for the fourth quarter rose to ₹1,720.30 crore (₹1,439.67 crore) boosted by 85% increase in CDMO business revenue to ₹490 crore (₹265 crore). Revenue from the mainstay generics business increased 5% to ₹1,230 crore (₹1,175 crore).
Generics revenue was pushed up by a 27% increase in finished dosage form (FDF) division revenue to ₹544 crore (₹430 crore). Revenue from active pharmaceutical ingredients (APIs) division, the other component of the generics business, declined 8% to ₹686 crore (₹745 crore).
For 2024-25, net profit increased to ₹354.41 crore (₹168.21 crore) and revenue from operations rose to ₹5,553.96 crore (₹5,040.83 crore). The company attributed the higher revenues to robust demand environment for CDMO offering and higher FDF sales.”
“These results demonstrate the strength of our business model and give us confidence in our outlook. Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence,” founder and CEO Satyanarayana Chava said.
₹0.80 interim dividend
The company’s has declared an interim dividend of ₹0.80 per equity share of ₹2 each. May 9 has been fixed as record date, for determining eligibility of the shareholders, and the dividend amount will be paid on or after May 20.
“Going ahead, we remain confident in our growth expectations as we look forward to execute on long lead programmes, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remain unchanged, prioritising investments into high value business opportunities,” CFO V.V. Ravi Kumar said.
Source: The Hindu
